Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease
Authors:
- Eric J SmallESEric J Small
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the PancreasAnnals of Surgery, 2004
- The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2003
- Radical Prostatectomy Nomograms in Black American Men: Accuracy and ApplicabilityJournal of Urology, 2003
- International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical ProstatectomyJournal of Clinical Oncology, 2002
- A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMAJournal of Urology, 2001
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update1997
- Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivoThe Prostate, 1992
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.Journal of Cell Biology, 1988
- Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3The Prostate, 1984